Literature DB >> 16248347

Bayesian designs with frequentist and Bayesian error rate considerations.

You-Gan Wang1, Denis Heng-Yan Leung, Ming Li, Say-Beng Tan.   

Abstract

So far, most Phase II trials have been designed and analysed under a frequentist framework. Under this framework, a trial is designed so that the overall Type I and Type II errors of the trial are controlled at some desired levels. Recently, a number of articles have advocated the use of Bayesian designs in practice. Under a Bayesian framework, a trial is designed so that the trial stops when the posterior probability of treatment is within certain prespecified thresholds. In this article, we argue that trials under a Bayesian framework can also be designed to control frequentist error rates. We introduce a Bayesian version of Simon's well-known two-stage design to achieve this goal. We also consider two other errors, which are called Bayesian errors in this article because of their similarities to posterior probabilities. We show that our method can also control these Bayesian-type errors. We compare our method with other recent Bayesian designs in a numerical study and discuss implications of different designs on error rates. An example of a clinical trial for patients with nasopharyngeal carcinoma is used to illustrate differences of the different designs.

Entities:  

Mesh:

Year:  2005        PMID: 16248347     DOI: 10.1191/0962280205sm410oa

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  4 in total

1.  A predictive probability design for phase II cancer clinical trials.

Authors:  J Jack Lee; Diane D Liu
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

2.  Bayes-LQAS: classifying the prevalence of global acute malnutrition.

Authors:  Casey Olives; Marcello Pagano
Journal:  Emerg Themes Epidemiol       Date:  2010-06-09

3.  The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials.

Authors:  Yanhong Zhou; Ruitao Lin; J Jack Lee
Journal:  Pharm Stat       Date:  2021-05-19       Impact factor: 1.234

4.  Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.

Authors:  Dung-Tsa Chen; Michael J Schell; William J Fulp; Fredrik Pettersson; Sungjune Kim; Jhanelle E Gray; Eric B Haura
Journal:  Transl Cancer Res       Date:  2019-07       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.